US Patent

US8535717 — Pharmaceutical composition

Formulation · Assigned to Sun Pharma Advanced Research Co Ltd · Expires 2026-02-22 · 0y expired

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an oral controlled release pharmaceutical composition containing levetiracetam or a derivative, in a unit dosage form with a rate-controlling agent or coating.

USPTO Abstract

The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: (a) a highly soluble high dose active ingredient consisting essentially of therapeutically effective amount of levetiracetam or a pharmaceutically acceptable derivative thereof, and (b) a rate controlling means comprising a rate-controlling agent and/or a coating selected from (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form, wherein the composition is in the form of a compact tablet and the levetiracetam or a pharmaceutically acceptable derivative thereof is present in an amount ranging from about 55% to about 90% by weight of the tablet.

Drugs covered by this patent

Patent Metadata

Patent number
US8535717
Jurisdiction
US
Classification
Formulation
Expires
2026-02-22
Drug substance claim
No
Drug product claim
Yes
Assignee
Sun Pharma Advanced Research Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.